L3VLUP
ProSign in

TAK · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TAKVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TAK
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterTAKVRTX
Q3 20204 holders, $423m31 holders, $21.9bn
Q4 20205 holders, $549m30 holders, $18.4bn
Q1 20214 holders, $699m31 holders, $15.4bn
Q2 20214 holders, $476m30 holders, $12.7bn
Q3 20214 holders, $410m35 holders, $10.1bn
Q4 20212 holders, $111m28 holders, $12.4bn
Q1 2022none listed holders, n.a.23 holders, $16.1bn
Q2 20223 holders, $69m25 holders, $18.1bn
Q3 20223 holders, $68m22 holders, $18.4bn
Q4 20225 holders, $208m28 holders, $18.4bn
Q1 20235 holders, $349m26 holders, $21.4bn
Q2 20235 holders, $353m27 holders, $24.7bn
Q3 20234 holders, $311m33 holders, $24.3bn
Q4 20235 holders, $374m32 holders, $28.6bn
Q1 20243 holders, $228m31 holders, $29.8bn
Q2 20244 holders, $243m29 holders, $33.4bn
Q3 20243 holders, $236m27 holders, $33.5bn
Q4 20243 holders, $271m26 holders, $28.5bn
Q1 20253 holders, $256m21 holders, $35.4bn
Q2 20252 holders, $257m21 holders, $32.3bn
Q3 20252 holders, $253m22 holders, $25.9bn
Q4 20254 holders, $355m26 holders, $31.8bn
Q1 20263 holders, $467m25 holders, $31.8bn
Q2 20263 holders, $410m26 holders, $34.6bn
TAK

Takeda Pharmaceutical Co Ltd

Holders
3
Reported value
$236m
Buyers
2
Sellers
1

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
27
Reported value
$33.5bn
Buyers
17
Sellers
10

Breadth +7 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TAK (0)

None.

Only VRTX (24)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Capital World Investors, D. E. Shaw & Co., Egerton Capital UK LLP, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →